Clinical Trial

Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine in subjects ( aged 6 months to 59 years ).
Trial Details
NCT Number NCT07326878
Lead Sponsor Institute of Medical Biology, Chinese Academy of Medical Sciences
Collaborators: The Second Affiliated Hospital of Chongqing Medical University
Conditions Hand, Foot and Mouth Disease (HFMD), HFMD, Hand, Foot and Mouth Disease
Enrollment 144 participants
Start Date 2025-12-30
Primary Completion 2026-08-15 (estimated)
Study Completion 2027-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-08